Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-Myositis
2025-521145-24-01Phase 2Authorised
- Sponsor
- Cabaletta Bio
- Start
- Apr 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of resecabtagene autoleucel in Autoimmune Myopathies, juvenile myositis (JM), dermatomyositis (DM) and 2 more, sponsored by Cabaletta Bio. Primary endpoint: Incidence and severity of adverse events. Planned start Apr 2026; status: authorised.
02
Drugs
resecabtagene autoleucel
03
Conditions
Autoimmune Myopathiesjuvenile myositis (JM)dermatomyositis (DM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on 2025-521145-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521145-24-01.